When looking at the clinical pathological features of patients within each RECPAM classes (please see profiles at the bottom of Figure 2A), we found that pre-operative serum levels of CEA were higher in patients with lowest mortality risk (and vice versa) while, although not statistically significant, the percentage of subjects with jaundice and stage IIB-cancer patients was slight higher within intermediate and highest mortality risk classes. This evidence concerns the gene CEACAM5 and Jaundice.